Cartesian Therapeutics, Inc. — Director's Dealing 2019

Aug 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2019-08-14

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-14	Common Stock	P	10000	$1.7415	Acquired	86418	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1237028	Indirect
Common Stock	445576	Indirect
Common Stock	4456597	Direct

Footnotes

F1: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.75. The Reporting Person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: LKST, Inc. is the general partner of Leukon Investments LP. Timothy Springer is the president of LKST, Inc. and the managing member of TAS Partners, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Leukon Investments LP and TAS Partners, LLC except to the extent of his pecuniary interest therein, if any.

F3: Held by Leukon Investments LP.

F4: Held by TAS Partners, LLC.